Login / Signup

The quest to deliver high-dose rifampicin: can the inhaled approach help?

Prakash KhadkaJack DummerPhilip C HillShyamal C Das
Published in: Expert opinion on drug delivery (2024)
Clinical trials suggest that an approximately 3-fold increase in the standard oral dose of rifampicin may be required for better clinical outcomes. On the other hand, animal studies suggest that inhaled rifampicin can deliver a high concentration of the drug to the lungs and achieve approximately double the plasma concentration than that from oral rifampicin. Clinical trials on inhaled antibiotics suggest that dry powder inhalation is a patient-friendly and well-tolerated approach in treating respiratory infections compared to conventional treatments. Rifampicin, a well-known anti-TB drug given orally, is a good candidate for clinical development as a dry powder inhaler.
Keyphrases
  • mycobacterium tuberculosis
  • clinical trial
  • pulmonary tuberculosis
  • high dose
  • cystic fibrosis
  • low dose
  • case report
  • phase ii
  • adverse drug
  • drug induced
  • case control